Peptides News and Research

RSS

Vitamin D: A multi-purpose nutrient for overall health

A string of recent discoveries about the multiple health benefits of vitamin D has renewed interest in this multi-purpose nutrient, increased awareness of the huge numbers of people who are deficient in it, spurred research and even led to an appreciation of it as "nature's antibiotic."

24 Nov 2009

C3a peptide regulates the generation of new nerve cells in the brain: Study

The generation of new nerve cells in the brain is regulated by a peptide known as C3a, which directly affects the stem cells' maturation into nerve cells and is also important for the migration of new nerve cells through the brain tissue, reveals new research from the Sahlgrenska Academy published in the journal Stem Cells.

23 Nov 2009

Study examines how dietary restriction and high-caloric diet influence biochemical responses

Researchers at Mount Sinai School of Medicine set out to address a question that has been challenging scientists for years: How do dietary restriction-and the reverse, overconsumption-produce protective effects against aging and disease?

23 Nov 2009

University of Michigan scientists discover how SEVI works

Since the discovery in 2007 that a component of human semen called SEVI boosts infectivity of the virus that causes AIDS, researchers have been trying to learn more about SEVI and how it works, in hopes of thwarting its infection-promoting activity.

20 Nov 2009

U.S. Patent Office approves multiple patent claims from Helix BioMedix

Helix BioMedix, Inc. (OTCBB: HXBM), a developer of bioactive peptides, today announced the United States Patent and Trademark Office has allowed multiple claims in one of the company’s recent patent applications. US patent application 12/005653, “Short Bioactive Peptides for Cellular and Immunological Modulation,” covers a number of peptides including Heptapeptide-7, a SmartPeptides™ technology and lead component in the Striking™ Skin Care line. The patent is expected to issue shortly.

20 Nov 2009

ScinoPharm receives Potent Compound Safety Certification from SafeBridge Consultants

ScinoPharm, a leading global supplier of active pharmaceutical ingredients (APIs), announced that its Tainan facility has received the Potent Compound Safety Certification from SafeBridge(R) Consultants, Inc.

20 Nov 2009

Unique life science-focused application for social media site launched

Sigma-Aldrich® today announced the launch of a unique life science-focused application for the social media site, Facebook. Developed and marketed by Sigma® Life Science, the 'What's Your Favorite Gene?' application is the first and currently only application of its kind available on Facebook, and provides a platform that can enable scientists and researchers to network with each other and facilitate discussion based on their favorite genes, identifiable via gene functionality and biological pathways.

19 Nov 2009

Cancer-fighting protein successfully placed directly into solid tumors and turned on

Experiments at the Pioneer Valley Life Sciences Institute (PVLSI) at Baystate Medical Center in Springfield, Mass., reported in a recent British Journal of Cancer, confirm that University of Massachusetts Amherst chemical engineer Neil Forbes' delivery and trigger system has for the first time successfully placed TRAIL, a cancer-fighting protein, directly into solid tumors and on cue, turned it on. The treatment improved the 30-day survival time of mice with mammary tumors from 0 to 100 percent.

18 Nov 2009

GRK2 inhibition protects against chronic heart failure

Inhibition of a protein known to contribute to heart failure also appears to be protective of the heart in more acute cardiac stress injury, namely ischemia reperfusion, according to two studies conducted at the Center for Translational Medicine at Thomas Jefferson University. The studies will be presented at the American Heart Association Scientific Sessions 2009 in Orlando, Fla.

18 Nov 2009

Targeting normal cells that surround cancer cells increases the effectiveness of traditional anti-cancer treatments

Targeting the normal cells that surround cancer cells within and around a tumor is a strategy that could greatly increase the effectiveness of traditional anti-cancer treatments, say researchers at The Wistar Institute.

17 Nov 2009

Flamel Technologies total revenues up $9.9 million in the third quarter 2009

Flamel Technologies today announced its financial results for the third quarter of 2009.

16 Nov 2009

Personal CGM improves glucose control for diabetes patients

In acknowledgement of this year’s World Diabetes Day, which calls on all those responsible for diabetes care to understand diabetes and take control, Medtronic, Inc. (NYSE: MDT) highlights the growing body of clinical evidence for Personal Continuous Glucose Monitoring (CGM) in improving glucose control for diabetes patients.

16 Nov 2009

Kun Run Biotechnology net revenue increases 65% for the quarter ended September 30, 2009

Kun Run Biotechnology, Inc., a leading bio-pharmaceutical company in China that focuses on manufacturing and sales of peptides and peptide-based drugs, today announced its financial results for the third quarter ended September 30, 2009.

13 Nov 2009

Mithridion reports progress with its potential oral small-molecule drugs for AD and schizophrenia

Mithridion, Inc., a biopharmaceutical company focusing on developing drugs for serious Central Nervous System (CNS) disorders, announced today progress with its pipeline of potential oral small-molecule drugs for Alzheimer's disease (AD) and schizophrenia.

13 Nov 2009

arGentis Pharmaceuticals to commence human clinical evaluation of ARG301 oral altered peptide ligand

arGentis Pharmaceuticals, LLC today announced that it will collaborate with the University of Tennessee Health Science Center (UTHSC) and the Veterans Affairs Medical Center of Memphis (VAMC) to initiate the first human clinical evaluation of an oral altered peptide ligand (APL), ARG301, in a Phase I study of Rheumatoid Arthritis patients.

12 Nov 2009

Review of Mersana Therapeutics's lead compound, XMT-1001 to be published

Mersana Therapeutics, a platform-based cancer therapeutics company, announced today that a review of the Company's lead compound, XMT-1001, will appear in the November 12, 2009 special issue of Advanced Drug Delivery Reviews on Polymer Therapeutics: Clinical Applications and Challenges for Development.

12 Nov 2009

Stapled Peptides directly inhibit the Notch transcription factor complex

Aileron Therapeutics, a biopharmaceutical company leading the development of a new class of drugs called Stapled Peptides, announced today that its collaborators, James E. Bradner, MD of the Dana-Farber Cancer Institute and the Broad Institute of Harvard and MIT, and Gregory L. Verdine, PhD, Professor of Chemistry at Harvard University, published research in Nature entitled, “Direct Inhibition of the Notch Transcription Factor Complex.”

12 Nov 2009

Stapled Peptides can inhibit key intracellular biological targets, says new research

Aileron Therapeutics, a biopharmaceutical company leading the development of a new class of drugs called Stapled Peptides, announced today that its collaborators, James E. Bradner, MD of the Dana-Farber Cancer Institute and the Broad Institute of Harvard and MIT, and Gregory L. Verdine, PhD, Professor of Chemistry at Harvard University, published research in Nature entitled, "Direct Inhibition of the Notch Transcription Factor Complex." Results presented in the paper showed that Stapled Peptides can potently and directly inhibit the transcription factor Notch, an oncogene implicated in cancer cell proliferation and survival.

12 Nov 2009

Scientists find way to disarm "undruggable" protein; discovery lays foundation for new kind of cancer therapy

Scientists have devised an innovative way to disarm a key protein considered to be "undruggable," meaning that all previous efforts to develop a drug against it have failed. Their discovery, published in the November 12 issue of Nature, lays the foundation for a new kind of therapy aimed directly at a critical human protein — one of a few thousand so-called transcription factors — that could someday be used to treat a variety of diseases, especially multiple types of cancer.

12 Nov 2009

New HPV vaccine eliminates chronic infection and reduces precancerous genital lesions in women

A new vaccine designed to stimulate an immune response against a cancer-causing human papillomavirus (HPV-16) can eliminate chronic infection by the virus and may cause regression of precancerous genital lesions in women who receive the vaccine.

11 Nov 2009

Peptides News and Research

Vitamin D: A multi-purpose nutrient for overall health

C3a peptide regulates the generation of new nerve cells in the brain: Study

Study examines how dietary restriction and high-caloric diet influence biochemical responses

University of Michigan scientists discover how SEVI works

U.S. Patent Office approves multiple patent claims from Helix BioMedix

ScinoPharm receives Potent Compound Safety Certification from SafeBridge Consultants

Unique life science-focused application for social media site launched

Cancer-fighting protein successfully placed directly into solid tumors and turned on

GRK2 inhibition protects against chronic heart failure

Targeting normal cells that surround cancer cells increases the effectiveness of traditional anti-cancer treatments

Flamel Technologies total revenues up $9.9 million in the third quarter 2009

Personal CGM improves glucose control for diabetes patients

Kun Run Biotechnology net revenue increases 65% for the quarter ended September 30, 2009

Mithridion reports progress with its potential oral small-molecule drugs for AD and schizophrenia

arGentis Pharmaceuticals to commence human clinical evaluation of ARG301 oral altered peptide ligand

Review of Mersana Therapeutics's lead compound, XMT-1001 to be published

Stapled Peptides directly inhibit the Notch transcription factor complex

Stapled Peptides can inhibit key intracellular biological targets, says new research

Scientists find way to disarm "undruggable" protein; discovery lays foundation for new kind of cancer therapy

New HPV vaccine eliminates chronic infection and reduces precancerous genital lesions in women

Editorial Focus eBook - Peptides and Oligonucleotides (2nd edition) eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News